Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer

Hoo, Linda Soo; Zhang, Jianying Y; Chan, Edward K. L.

doi:10.1038/sj.onc.1205625

Cited by 124 publications

(121 citation statements)

References 34 publications

(39 reference statements)

Supporting

Mentioning

117

Contrasting

Order By: Relevance

“…In the case of HCC, the natural conditions would be chronic hepatitis and liver cirrhosis. The basis for the notion of the necessity of customized panels of TAAs is based not only on empirical observations but also on retrospective analysis of our own data accumulated in previously published work [4][5][6][14][15][16][17]30]. The main purpose of this study is to identify a specific panel of TAAs for HCC and compare and contrast this with chronic hepatitis and liver cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

“…Such autoantibodies from patients with hepatocellular carcinoma (HCC) have been used to immunoscreen cDNA expression libraries, and several novel TAAs such as HCC1 [4], p62 [5] and p90 [6] have been isolated and characterized. The hypothesis is that in sera from HCC patients who show autoantibody changes during progression from chronic liver disease to HCC, the novel autoantibodies appearing with malignant transformation will be more likely to be related to events associated with tumorigenesis, and that these autoantibodies can be used as reporters identifying aberrant cellular mechanisms in tumorigenesis, and also serve as immunodiagnostic markers for cancer detection [1].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma

Zhang

Megliorino

Peng

et al. 2007

Journal of Hepatology

113

View full text Add to dashboard Cite

Background/Aims-Previous studies have demonstrated that during transition from chronic liver disease to hepatocellular carcinoma (HCC), autoantibodies can appear which are not detected in the prior pre-malignant conditions. These antibody responses may be stimulated by cellular proteins involved in carcinogenesis. This study determines the prevalence of antibodies to a selected panel of eight tumor-associated antigens (TAAs) in sera from patients with chronic hepatitis, liver cirrhosis and HCC, and considers the possibility and usefulness of antibodies to such a panel of TAAs in differentiating between these conditions. The panel of eight TAAs includes Imp1, p62, Koc, p53, cmyc, cyclin B1, survivin and p16 full-length recombinant proteins.Methods-Enzyme-linked immunosorbent assay (ELISA) was used to detect antibodies against eight selected TAAs in 30 sera from chronic hepatitis, 30 from liver cirrhosis, and 142 from HCC. Positive results were also confirmed by slot blot, Western blotting and immunoprecipitation assay.Results-Antibody frequency to any individual TAA in HCC varied from 9.9%-21.8%. With the successive addition of TAAs to a final total of eight antigens, there was a stepwise increase of positive antibody reactions reaching a frequency of 59.8% with whole cohort of HCC patients. This was significantly higher than the frequency of antibodies in chronic hepatitis (20%), liver cirrhosis (30%) and normal individuals (12.2%).Conclusions-This study demonstrates that malignant transition to HCC is associated with increased autoantibody responses to certain cellular proteins which might have a role in tumorigenesis, and shows that a mini-array of eight TAAs enhanced antibody detection for diagnosis of HCC. More studies in patients with HCC and precursor conditions such as chronic hepatitis, alcoholic hepatitis and liver cirrhosis using enlarged TAA mini-array panels might further improve the sensitivity and specificity of this mode of cancer immunodiagnosis. Its additional usefulness might be in the early detection of cancer in some patients with predisposing conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma

Zhang

Megliorino

Peng

et al. 2007

Journal of Hepatology

113

View full text Add to dashboard Cite

show abstract

“…In contrast, there are no data available, to our knowledge that associates autoantibodies against p53 with patients' clinical characteristics. In patients with colorectal cancer (CRC), there is an increase in the prevalence of anti-p53 autoantibodies in carcinoma in-situ (6%) compared with adenomas (1%), indicating that the level of anti-p53 autoantibody increases with CRC [36] hnRNP L Akada et al [42] HSP70, SOD2, and PRDX6 Shao et al [41] Glucose-regulated protein 78 Nomura et al [39] Ku86 Liu et al [40] CENPF, DDX3, HSPA4, HSPA5, VIM, LMNB1, and p53 Pekáriková et al [21] CRT Chen et al [28] Sui1, RalA Wang et al [43] KRT23, AHSG and FTL Wang et al [44] RalA Looi et al [45] HSP60, HSP70 Li et al [35] DDX3, eEF2, AIF, hnRNP A2, PBP, and TIM Chen et al [46] EIF3SI, LDHA, RFC2, and MCART1 Zhang et al [27] IMP1, IMP2, IMP3, p53, c-myc, cyclin B1, survivin and p16 Akere et al [13] p53 Zhou et al [47] HCC-22-5 Takashima et al [48] HSP70, GAPDH, PRX, Mn-SOD Looi et al [49] p16 Yagihashi et al [25] Survivin Su et al [17] IMP2 Himoto et al [19] IMPs Himoto et al [18] IMPs, p53, c-myc, and survivin Zhang et al [24] c-myc, cyclin B1, IMP1, Koc, p53, IMP2, and survivin Soo Hoo et al [50] p53, IMP2, Koc, CENP-F, p90 Le Naour et al [51] CRT, CK8, NDK-A, and ATP5B Zhang et al [23] IMP2, CENPF Zhang et al [20] IMP2 Raedle et al [52] p53 Covini et al [22] Cyclin B1 Imai et al [53] HCC1 TAAs: Tumor-associated antigens; HCC: Hepatocellular carcinoma; IMP: Insulin-like growth factor mRNA-binding; CENPF: Centromere protein F. 9…”

Section: Association Of the Prevalence Of Autoantibodies With The CLImentioning

confidence: 99%

Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

Huang

2015

WJH

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide. The survival rate after the onset of symptoms is generally less than one year for the late presentation of HCC, and reliable tools for early diagnosis are lacking. Therefore, novel biomarkers for the early detection of HCC are urgently required. Recent studies show that the abnormal release of proteins by tumor cells can elicit humoral immune responses to self-antigens called tumor-associated antigens (TAAs). The corresponding autoantibodies can be detected before the clinical diagnosis of cancer. Therefore, there is growing interest in using serum autoantibodies as cancer biomarkers. In this review, we focus on the advances in research on autoantibodies against TAAs as serum biomarker for detection of HCC, the mechanism of the production of TAAs, and the association of autoantibodies with patients' clinical characteristics.

show abstract

“…The rationale is that intracellular proteins which are involved in carcinogenesis are provoking autoantibody responses and therefore autoantibodies can be used to immunoscreen cDNA expression libraries to isolate, identify and characterize proteins which might potentially be involved in malignant transformation. Using this approach, we have successfully isolated several novel TAAs such as p62 [7] and p90 [18]. A proteome-based approach has been recently implemented for identifying tumor-associated antigens in cancer patients [20].…”

Section: Identification Of Taasmentioning

confidence: 99%

“…With these two techniques, we identify sera which have high-titer fluorescent staining or strong signals to cell extracts on Western blotting and subsequently use the antibodies in these sera to isolate cDNA clones from cDNA expression libraries. In this manner, several novel TAAs including HCC1 [15], SG2NA [16], CENP-F [17], p62 [7] and p90 [18] have been identified. Several novel as well as previously defined tumor antigens have been recently identified with autoantibodies from patients with different types of cancer [3] using a methodology called SEREX (serological analysis of recombination cDNA expression libraries) [19].…”

Section: Identification Of Taasmentioning

confidence: 99%

Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma

Zhang¹

2007

Autoimmunity Reviews

View full text Add to dashboard Cite

Liver cancer, especially hepatocellular carcinoma (HCC), is particularly prevalent in Africa and Asia. HCC affects the Hispanic population of the United States at a rate double that of the white population. The majority of people with HCC will die within 1 year of its detection. This high case-fatality rate can in part be attributed to lack of diagnostic methods that allow early detection. How to establish a methodology to identify the high-risk individuals for HCC remains to be investigated. The multifactorial and multi-step nature in the molecular pathogenesis of human cancers must be taken into account in both the design and interpretation of studies to identify markers which will be useful for early detection of cancer. Our recent studies demonstrated that a mini-array of multiple tumorassociated antigens (TAAs) might enhance autoantibody detection for diagnosis of HCC, especially for the alpha fetoprotein (AFP)-negative cases. It also suggested that different types of cancer might require different panels of TAAs to achieve the sensitivity and specificity required to make immunodiagnosis a feasible adjunct to tumor diagnosis.

show abstract

Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer

Cited by 124 publications

References 34 publications

Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma

Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma

Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma

Contact Info

Product

Resources

About